Three-month variation of plasma @entity40590 compared with @entity1851 , albumin and homocysteine levels in haemodialysis XXXX .

@entity1 @entity7166 @entity40590 @entity1851
BACKGROUND: Inflammatory markers vary considerably over time in haemodialysis (HD) @entity1 , yet the variability is poorly defined. The aim of the study was to assess changes of plasma levels of @entity40590 ( @entity40590 ), @entity1851 ( @entity1851 ), albumin and homocysteine (Hcy) over 3 months and the association between the changes in these biomarkers and mortality. METHODS: In 188 prevalent HD @entity1 , inflammatory markers were measured at inclusion and after 3 months. Mortality was recorded during a median follow-up of 41 months. The changes of the biomarker levels were categorized according to change in tertile for the specific biomarker. The variation was calculated as the @entity7166 ( @entity7166 ). Mortality was analysed by Kaplan-Meier and Cox proportional hazards model. The predictive strength was calculated for single measurements and for the variation of each inflammatory marker. RESULTS: The intra-individual variation (low @entity7166 ) was largest for @entity40590 [ @entity7166 0.44; 95% confidence interval (CI): 0.33-0.55], albumin ( @entity7166 0.58; 95% CI: 0.49-0.67) and @entity1851 ( @entity7166 0.59; 95% CI: 0.51-0.68) and lowest for Hcy ( @entity7166 0.81; 95% CI: 0.77-0.86). During follow-up, 88 @entity1 died. CONCLUSIONS: @entity40590 measurements are less stable and show higher variation within @entity1 than @entity1851 , albumin and Hcy. Persistently elevated @entity40590 levels are associated with high mortality. Moreover, in multivariate logistic regression we found that stable high @entity40590 adds to the mortality risk, even after inclusion of clinical factors and the three other biomarkers. The associations of decreasing albumin levels as well as low Hcy levels with worse outcome reflect protein-energy wasting.
